2021
1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?
Nguyen D, Bethel C, Taracilla M, Li Q, Dousa K, Kurz S, Nguyen L, Kreiswirth B, Boom W, Bonomo R. 1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)? Open Forum Infectious Diseases 2021, 8: 780-780. PMCID: PMC8643912, DOI: 10.1093/ofid/ofab466.1582.Peer-Reviewed Original ResearchB-lactamMultidrug-resistant TBTreatment of TBNovel therapiesMtb H37RvAvibactamRelebactamCarbapenemsClavulanateMicrodilution methodAcyl-enzyme complexTherapeutic potentialDurlobactamMeropenemMICDual actionTranspeptidasePre-incubationDiazabicyclooctaneMtbAmoxicillinPeriod of pre-incubationTuberculosis
2020
Drug-Resistant Tuberculosis A Glance at Progress and Global Challenges
Dousa K, Kurz S, Bark C, Bonomo R, Furin J. Drug-Resistant Tuberculosis A Glance at Progress and Global Challenges. Infectious Disease Clinics Of North America 2020, 34: 863-886. PMID: 33011048, DOI: 10.1016/j.idc.2020.06.001.Peer-Reviewed Original ResearchConceptsSecond-line medicationsMultidrug-resistant Mycobacterium tuberculosisDrug susceptibility predictionOral formulationMultinational trialDrug resistancePublic health threatEconomic burdenDiagnostic techniquesTuberculosisAdequate clinical resourcesClinical resourcesHealth threatLaboratory services
2017
Drug Resistance Assays for Mycobacterium tuberculosis
Kurz S, Salfinger M. Drug Resistance Assays for Mycobacterium tuberculosis. 2017, 1359-1365. DOI: 10.1007/978-3-319-47266-9_33.Peer-Reviewed Original ResearchDetection of drug resistanceEpidemic of drug-resistant tuberculosisAgar proportion methodAntimicrobial susceptibility testingDrug-resistant tuberculosisDrug resistance assaysDetection of patientsDrug-resistant Mycobacterium tuberculosis strainsMycobacterium tuberculosis strainsMinimal inhibitory concentrationPharmacodynamic correlationsSusceptibility testingDrug resistanceLiquid medium systemsEffective treatmentTuberculosis strainsScreening testProportion methodGenotyping methodsResistance assaysBacteriological methodsInhibitory concentrationMycobacterium tuberculosisTuberculosisPatients
2015
Inhibiting the β‑Lactamase of Mycobacterium tuberculosis (Mtb) with Novel Boronic Acid Transition-State Inhibitors (BATSIs)
Kurz S, Hazra S, Bethel C, Romagnoli C, Caselli E, Prati F, Blanchard J, Bonomo R. Inhibiting the β‑Lactamase of Mycobacterium tuberculosis (Mtb) with Novel Boronic Acid Transition-State Inhibitors (BATSIs). ACS Infectious Diseases 2015, 1: 234-242. PMID: 27622739, DOI: 10.1021/acsinfecdis.5b00003.Peer-Reviewed Original Research
2012
Reappraising the use of β-lactams to treat tuberculosis
Kurz S, Bonomo R. Reappraising the use of β-lactams to treat tuberculosis. Expert Review Of Anti-infective Therapy 2012, 10: 999-1006. PMID: 23106275, PMCID: PMC3728824, DOI: 10.1586/eri.12.96.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply